Holen Sie sich die Stockscreener-App
45.81
3.67%
1.62
Schlusskurs vom Vortag:
$44.19
Offen:
$44.94
24-Stunden-Volumen:
1.04M
Relative Volume:
0.79
Marktkapitalisierung:
$3.68B
Einnahmen:
$541.74M
Nettoeinkommen (Verlust:
$88.01M
KGV:
42.17
EPS:
1.0862
Netto-Cashflow:
$155.34M
1W Leistung:
+0.84%
1M Leistung:
+2.07%
6M Leistung:
+42.05%
1J Leistung:
+28.57%
1-Tages-Spanne:
$44.41
$46.09
1-Wochen-Bereich:
$44.18
$47.52
52-Wochen-Spanne:
$29.45
$60.91
Veracyte Inc Stock (VCYT) Company Profile
Firmenname
Veracyte Inc
Sektor
Branche
Telefon
(650) 243-6300
Adresse
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT vs TMO, DHR, NTRA, A, IQV
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
45.81 | 3.65B | 541.74M | 88.01M | 155.34M | 1.0862 |
TMO
Thermo Fisher Scientific Inc
|
654.80 | 241.26B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
214.06 | 150.48B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
410.35 | 59.47B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
167.78 | 48.71B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
258.21 | 44.50B | 16.63B | 1.39B | 2.12B | 8.0674 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-13 | Eingeleitet | Jefferies | Buy |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Underweight |
| 2025-10-20 | Eingeleitet | Canaccord Genuity | Hold |
| 2025-03-20 | Eingeleitet | Craig Hallum | Buy |
| 2024-12-05 | Herabstufung | Goldman | Buy → Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-16 | Eingeleitet | UBS | Buy |
| 2024-10-10 | Eingeleitet | Guggenheim | Buy |
| 2024-02-23 | Bestätigt | Needham | Buy |
| 2023-01-18 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-01-07 | Eingeleitet | Stephens | Overweight |
| 2021-11-18 | Fortgesetzt | Goldman | Buy |
| 2021-06-15 | Eingeleitet | Raymond James | Outperform |
| 2021-02-18 | Fortgesetzt | Needham | Buy |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Underweight |
| 2019-07-31 | Eingeleitet | Lake Street | Buy |
| 2019-07-02 | Eingeleitet | Needham | Buy |
| 2018-11-29 | Herabstufung | Janney | Buy → Neutral |
| 2018-10-31 | Hochstufung | Janney | Neutral → Buy |
| 2017-11-07 | Herabstufung | Janney | Buy → Neutral |
| 2017-11-07 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-08-31 | Fortgesetzt | BTIG Research | Buy |
| 2016-11-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2015-12-18 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-06-11 | Bestätigt | Leerink Partners | Outperform |
| 2013-11-26 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Veracyte Inc Aktie (VCYT) Neueste Nachrichten
Neogen Stock Rallies 83% YTD: What's Driving the Surge? - Zacks Investment Research
Veracyte, Inc. (VCYT) Stock Forecasts - Yahoo Finance
ETFs Investing in Veracyte, Inc. Stocks - TradingView
Preferred dividends of Veracyte, Inc. – HAN:12V - TradingView
Veracyte, Inc. Cash Flow – HAN:12V - TradingView
Veracyte, Staar Surgical, Corning - TradingView
Veracyte’s Decipher test shows predictive value in prostate cancer - Investing.com
Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation - marketscreener.com
For 44% with low scores, added hormone therapy showed no statistically significant benefit against 10-year cancer spread. - Stock Titan
Veracyte Inc. R (12V.MU) Q1 FY2026 earnings call transcript - Yahoo Finance
Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026 - The Manila Times
Eight studies will examine who with prostate cancer may benefit from more treatment - Stock Titan
Veracyte (VCYT) Surges 10.8%: Is This an Indication of Further Gains? - Yahoo Finance
Form 144 VERACYTE For: 25 September By Investing.com - Investing.com South Africa
Form 144 VERACYTE For: 25 September - Investing.com India
Veracyte stock rises 10.77 percent toward its yearly high - AD HOC NEWS
Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today - Eastern Progress
Is Veracyte Inc (VCYT) Overvalued After 10.8% Rally? GF Value Sa - GuruFocus
A Veracyte (VCYT) director plans a $352,500 share sale after selling 5,000 shares. - Stock Titan
Veracyte Insiders Sold US$1.3m Of Shares Suggesting Hesitancy - Moomoo
Understanding Momentum Shifts in (VCYT) - Stock Traders Daily
Veracyte global chief commercial off. John Leite sells $160,600 stock By Investing.com - Investing.com Canada
Form 4 Veracyte Inc For: 23 September - Investing.com India
Insider Sell: Global Chief Commercial Officer John Leite Sells 4 - GuruFocus
Veracyte global chief commercial off. John Leite sells $160,600 stock - Investing.com
Form 4 Veracyte Inc For: 23 September By Investing.com - Investing.com Australia
Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets - Benzinga
A Look at Veracyte Inc (VCYT) After 4.4% Gain -- GF Value $39.14 vs Price $41.52 - GuruFocus
Veracyte (NASDAQ: VCYT) officer to sell 4,015 shares under Rule 144 - Stock Titan
Veracyte (NASDAQ:VCYT) Offers Affordable Growth Backed by Strong Health and Cash Flow - ChartMill
Piper Sandler Maintains Veracyte(VCYT.US) With Buy Rating, Maintains Target Price $54 - Moomoo
Veracyte Inc. (NASDAQ: VCYT) Director Holstein Jens Disposes 5,000 Shares at $40.95 Each - Kalkine Media
Veracyte (VCYT) Dropped, But What Is Driving Attention Now? - simplywall.st
Director Jens Holstein Sells 5,000 Shares of Veracyte (VCYT) - GuruFocus
A Look at Veracyte Inc (VCYT) After 4.1% Decline -- GF Value $39 - GuruFocus
Veracyte Director Jens Holstein Executes Sale of 5,000 Shares Under 10b5-1 Plan - Kalkine Media
Veracyte (VCYT) director offloads 5,000 shares under plan - Stock Titan
Craig-Hallum Maintains Veracyte(VCYT.US) With Buy Rating - Moomoo
Veracyte Adds Another Stream to Bladder Franchise, UBS Says - marketscreener.com
Veracyte at Morgan Stanley conference: growth, deals and new tests By Investing.com - Investing.com Nigeria
Veracyte at Morgan Stanley conference: growth, deals and new tests - Investing.com
Needham reiterates Veracyte stock rating at Buy on genomics deal By Investing.com - Investing.com Nigeria
Needham Maintains Veracyte(VCYT.US) With Buy Rating, Maintains Target Price $69 - Moomoo
Needham reiterates Veracyte stock rating at Buy on genomics deal - Investing.com
Veracyte acquires Convergent Genomics for up to $180 million By Investing.com - Investing.com Australia
VCYT Looks 5.7% Overvalued on GF Value™ as Insider Selling Persi - GuruFocus
VCYT Looks 5.7% Overvalued on GF Value™ After Convergent Genomics Acquisition - GuruFocus
Veracyte acquires Convergent Genomics for up to $180 million - Investing.com
Veracyte Buys Convergent Genomics - marketscreener.com
Finanzdaten der Veracyte Inc-Aktie (VCYT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Veracyte Inc-Aktie (VCYT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Leite John | Global Chief Commercial Off |
Sep 21 '26 |
Sale |
40.00 |
4,015 |
160,600 |
124,329 |
0.97%
0.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):